Sen. Bernie Sanders highlighted a potential shift in the pricing of Ozempic during a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered the drug’s list price.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
